Abstract
BackgroundWe previously reported a correlation between small doses of oxaliplatin penetrating onto the spinal cord and acute pain after chemotherapy. Here, we propose that MT2 within the spinal dorsal horns participates in the development of oxaliplatin-induced neuropathic pain and may be a pharmacological target for the prevention and treatment of chemotherapy-induced peripheral neuropathy (CIPN).MethodsThe rat model of CIPN was established by 5 consecutive injections of oxaliplatin (0.4 mg/100 g/day). Genetic restoration of neuron-specific metallothionein-2 was implemented 21 days before oxaliplatin treatment, and also, genetic inhibition by metallothionein-2 siRNA was performed. Mechanical allodynia and locomotor activity were assayed. Cell-specific expression of metallothionein-2, the mRNA levels of pro-inflammatory cytokines, nuclear translocation of NF-κB, the protein levels of expression of IκB-α, and interaction between IκB-α and P65 were evaluated in the spinal dorsal horns. Also, in vitro interaction of sequentially deleted IκB-α promoter with metallothionein-2 was used to assess the signal transduction mechanism.ResultsWe found that oxaliplatin induced downregulation of metallothionein-2 in rat spinal cord neurons. By contrast, genetic restoration of metallothionein-2 in the spinal dorsal horn neuron blocked and reversed neuropathic pain in oxaliplatin-treated rats of both sexes, whereas genetic inhibition of metallothionein-2 triggered neuropathic pain in normal rats. Overall locomotor activity was not impaired after the genetic alterations of metallothionein-2. At the molecular level, metallothionein-2 modulated oxaliplatin-induced neuroinflammation, activation of NF-κB, and inactive transcriptional expression of IκB-α promoter, and these processes could be blocked by genetic restoration of metallothionein-2 in the spinal dorsal horn neurons.ConclusionsMetallothionein-2 is a potential target for the prevention and treatment of CIPN. A reduction of NF-κB activation and inflammatory responses by enhancing the transcription of IκB-α promoter is proposed in the mechanism.
Highlights
Oxaliplatin, a third-generation platinum-based antitumor drug, is commonly used to treat many types of solid tumors [1, 2]
Oxaliplatin downregulated MT2 in the spinal dorsal horn neurons of male rats We demonstrated the role of MT2 in chemotherapy-induced peripheral neuropathy (CIPN) by first examining the cell-specific MT2 abundance in the spinal cord in conjunction with the behavioral responses in male rats after consecutive administrations of oxaliplatin
These data showed an association between the downregulation of MT2 in the spinal dorsal horn neurons and oxaliplatin-induced neuropathic pain, indicating a potential role for MT2 in the development of CIPN
Summary
Oxaliplatin, a third-generation platinum-based antitumor drug, is commonly used to treat many types of solid tumors [1, 2]. More than 90% of all cancer patients treated with oxaliplatin experience acute, transient sensory disturbances in the distal extremities These usually resolve within a few days, 20–54% of treated patients complain of persistent neuropathy with chronic pain [3,4,5,6]. This painful oxaliplatin-induced peripheral neuropathy can last up to 5 years beyond the end of the chemotherapy [7] and has a deleterious impact on the quality of life of cancer survivors and patients under treatment [8, 9]. We propose that MT2 within the spinal dorsal horns participates in the development of oxaliplatin-induced neuropathic pain and may be a pharmacological target for the prevention and treatment of chemotherapy-induced peripheral neuropathy (CIPN)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
